Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
Blood. 2012 Jan 12;119(2):521-9. doi: 10.1182/blood-2011-09-379966. Epub 2011 Nov 10.
Analysis of the chronic lymphocytic leukemia (CLL) coding genome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentation. Here, we assessed the prognostic role of NOTCH1 mutations in CLL. Two series of newly diagnosed CLL were used as training (n = 309) and validation (n = 230) cohorts. NOTCH1 mutations occurred in 11.0% and 11.3% CLL of the training and validation series, respectively. In the training series, NOTCH1 mutations led to a 3.77-fold increase in the hazard of death and to shorter overall survival (OS; P < .001). Multivariate analysis selected NOTCH1 mutations as an independent predictor of OS after controlling for confounding clinical and biologic variables. The independent prognostic value of NOTCH1 mutations was externally confirmed in the validation series. The poor prognosis conferred by NOTCH1 mutations was attributable, at least in part, to shorter treatment-free survival and higher risk of Richter transformation. Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL. NOTCH1 mutations are an independent predictor of CLL OS, tend to be mutually exclusive with TP53 abnormalities, and identify cases with a dismal prognosis.
对慢性淋巴细胞白血病 (CLL) 编码基因组的分析最近揭示,NOTCH1 原癌基因在 CLL 发病时经常发生突变。在这里,我们评估了 NOTCH1 突变在 CLL 中的预后作用。两个新诊断的 CLL 系列被用作训练 (n = 309) 和验证 (n = 230) 队列。NOTCH1 突变分别发生在训练系列和验证系列中的 11.0%和 11.3%的 CLL 中。在训练系列中,NOTCH1 突变使死亡风险增加了 3.77 倍,并导致总生存期 (OS) 缩短 (P <.001)。多变量分析在控制混杂的临床和生物学变量后,选择 NOTCH1 突变作为 OS 的独立预测因子。NOTCH1 突变的独立预后价值在验证系列中得到了外部证实。NOTCH1 突变导致的不良预后至少部分归因于无治疗缓解期较短和 Richter 转化风险较高。尽管在训练和验证系列中,NOTCH1 突变患者的 TP53 缺失超过 90%,但 NOTCH1 突变预测的 OS 与 TP53 突变/缺失的 CLL 相似。NOTCH1 突变是 CLL OS 的独立预测因子,倾向于与 TP53 异常相互排斥,并确定预后不良的病例。